Axon Enterprise, Inc $AXON Shares Acquired by Legal & General Group Plc

Legal & General Group Plc boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 426,533 shares of the biotechnology company’s stock after purchasing an additional 5,419 shares during the period. Legal & General Group Plc’s holdings in Axon Enterprise were worth $242,241,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. SLT Holdings LLC lifted its stake in Axon Enterprise by 64.0% during the fourth quarter. SLT Holdings LLC now owns 564 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 220 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in Axon Enterprise by 9.5% during the fourth quarter. Hantz Financial Services Inc. now owns 761 shares of the biotechnology company’s stock valued at $432,000 after purchasing an additional 66 shares during the last quarter. Swedbank AB lifted its stake in Axon Enterprise by 1.7% during the fourth quarter. Swedbank AB now owns 110,683 shares of the biotechnology company’s stock valued at $62,860,000 after purchasing an additional 1,820 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in Axon Enterprise by 2.4% during the fourth quarter. Coldstream Capital Management Inc. now owns 7,088 shares of the biotechnology company’s stock valued at $4,025,000 after purchasing an additional 166 shares during the last quarter. Finally, St. Louis Trust Co acquired a new stake in Axon Enterprise during the fourth quarter valued at approximately $866,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeri Williams sold 157 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total value of $76,930.00. Following the completion of the sale, the director owned 1,159 shares in the company, valued at approximately $567,910. This represents a 11.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Jennifer H. Mak sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,855 shares of company stock worth $2,907,428 in the last quarter. Insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Up 1.6%

Shares of NASDAQ:AXON opened at $391.32 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The company has a market cap of $31.54 billion, a PE ratio of 157.16, a price-to-earnings-growth ratio of 7.01 and a beta of 1.44. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The firm has a 50 day simple moving average of $410.07 and a 200 day simple moving average of $496.12.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating the consensus estimate of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.47 EPS. As a group, research analysts expect that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. JPMorgan Chase & Co. increased their target price on shares of Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. UBS Group reduced their price target on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.